JP7699205B2 - 抗ウイルスプロドラッグ化合物 - Google Patents

抗ウイルスプロドラッグ化合物 Download PDF

Info

Publication number
JP7699205B2
JP7699205B2 JP2023521833A JP2023521833A JP7699205B2 JP 7699205 B2 JP7699205 B2 JP 7699205B2 JP 2023521833 A JP2023521833 A JP 2023521833A JP 2023521833 A JP2023521833 A JP 2023521833A JP 7699205 B2 JP7699205 B2 JP 7699205B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
group
optionally substituted
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023521833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546565A (ja
JP2023546565A5 (https=
Inventor
リン チー
Original Assignee
リガンド・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リガンド・ファーマシューティカルズ・インコーポレイテッド filed Critical リガンド・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2023546565A publication Critical patent/JP2023546565A/ja
Publication of JP2023546565A5 publication Critical patent/JP2023546565A5/ja
Application granted granted Critical
Publication of JP7699205B2 publication Critical patent/JP7699205B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023521833A 2020-10-21 2021-10-19 抗ウイルスプロドラッグ化合物 Active JP7699205B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094728P 2020-10-21 2020-10-21
US63/094,728 2020-10-21
PCT/US2021/055608 WO2022086958A1 (en) 2020-10-21 2021-10-19 Antiviral prodrug compounds

Publications (3)

Publication Number Publication Date
JP2023546565A JP2023546565A (ja) 2023-11-06
JP2023546565A5 JP2023546565A5 (https=) 2024-10-28
JP7699205B2 true JP7699205B2 (ja) 2025-06-26

Family

ID=81290062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521833A Active JP7699205B2 (ja) 2020-10-21 2021-10-19 抗ウイルスプロドラッグ化合物

Country Status (4)

Country Link
US (1) US20230391807A1 (https=)
EP (1) EP4232456A4 (https=)
JP (1) JP7699205B2 (https=)
WO (1) WO2022086958A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102708995B1 (ko) 2018-01-10 2024-09-23 누코리온 파마슈티컬스, 인코포레이티드. 포스포르(포스포론)아미다타세탈 및 포스프(온)아탈세탈 화합물
MX2022000573A (es) 2019-07-17 2022-02-10 Nucorion Pharmaceuticals Inc Compuestos ciclicos de desoxirribonucleotido.
WO2021216431A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Benzyloxy phosph(on)ate compounds
CN119080837B (zh) * 2024-11-07 2025-03-11 上海柯君医药科技有限公司 一种抗病毒药物及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000293A1 (en) 1980-07-18 1982-02-04 Engels J Substituted adenosine-3',5'-phosphobenzyl triester derivatives,method for their preparation and medicaments containing such compounds
US20060100166A1 (en) 2002-06-07 2006-05-11 Kylix B.V. Compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
US20100081628A1 (en) 2008-06-11 2010-04-01 Pharmasset, Inc. Nucleoside cyclicphosphates
US20130315867A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2014204831A1 (en) 2013-06-18 2014-12-24 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20170044205A1 (en) 2014-04-16 2017-02-16 Idenix Pharmaceuticals Llc 3'-substituted methyl or alkynyl nucleosides nucleotides for the treatment of hcv
WO2017223020A1 (en) 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2019169323A1 (en) 2018-03-02 2019-09-06 January Therapeutics, Inc. Nanoparticle compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007027248A2 (en) * 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
MX2021012894A (es) * 2019-04-22 2021-11-17 Ligand Pharm Inc Compuestos ciclicos de fosfato.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000293A1 (en) 1980-07-18 1982-02-04 Engels J Substituted adenosine-3',5'-phosphobenzyl triester derivatives,method for their preparation and medicaments containing such compounds
US20060100166A1 (en) 2002-06-07 2006-05-11 Kylix B.V. Compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
US20100081628A1 (en) 2008-06-11 2010-04-01 Pharmasset, Inc. Nucleoside cyclicphosphates
US20130315867A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2014204831A1 (en) 2013-06-18 2014-12-24 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20170044205A1 (en) 2014-04-16 2017-02-16 Idenix Pharmaceuticals Llc 3'-substituted methyl or alkynyl nucleosides nucleotides for the treatment of hcv
WO2017223020A1 (en) 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2019169323A1 (en) 2018-03-02 2019-09-06 January Therapeutics, Inc. Nanoparticle compositions

Also Published As

Publication number Publication date
EP4232456A1 (en) 2023-08-30
JP2023546565A (ja) 2023-11-06
US20230391807A1 (en) 2023-12-07
WO2022086958A1 (en) 2022-04-28
EP4232456A4 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
JP7699205B2 (ja) 抗ウイルスプロドラッグ化合物
JP7661235B2 (ja) 環状リン酸エステル化合物
TWI838355B (zh) 5-氟尿嘧啶化合物
CN115605492B (zh) 核苷酸前药化合物
US20190100551A1 (en) 5-fluorouridine monophosphate cyclic triester compounds
JP2026032020A (ja) ベンジルオキシリン酸エステル（ホスホン酸エステル）化合物
EP4335496A2 (en) Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
JP7625542B2 (ja) 環状デオキシリボヌクレオチド化合物
RU2836016C2 (ru) Циклические дезоксирибонуклеотидные соединения
US20250188111A1 (en) Cyclic phosphoramidate compounds
HK40108726A (en) Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
KR20260062967A (ko) 사이클릭 포스페이트 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250616

R150 Certificate of patent or registration of utility model

Ref document number: 7699205

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150